{
    "clinical_study": {
        "@rank": "151466", 
        "arm_group": {
            "arm_group_label": "Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo diffusion-weighted MRI within 4 weeks of radiation start (baseline), during the second week of radiation therapy, during the fourth week of radiation therapy, and at 3 months after radiation therapy (post-treatment). Patients also undergo standard of care 4D CT and FDG-PET at the same time points."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies diffusion-weighted magnetic resonance imaging (MRI) in\n      identifying and localizing tumors in patients with non-small cell lung cancer undergoing\n      radiation therapy. Diagnostic procedures such as diffusion weighted MRI may help identify\n      where active cancer is to improve the targeting accuracy of radiotherapy. Comparing results\n      of diagnostic procedures done before, during, and after radiation therapy may help determine\n      how the location and volume of tumors changes over time and predict how the tumor will\n      respond to therapy."
        }, 
        "brief_title": "Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Non-small Cell Lung Cancer", 
            "Stage IIA Non-small Cell Lung Cancer", 
            "Stage IIB Non-small Cell Lung Cancer", 
            "Stage IIIA Non-small Cell Lung Cancer", 
            "Stage IIIB Non-small Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Assess diffusion-weighted MRI as an early predictor for tumor response in patients with\n      locally advanced (LA)-non-small cell lung cancer (NSCLC).\n\n      II. Establish the potential of individualized radiotherapy targeting of radioresistant tumor\n      sub-volumes.\n\n      OUTLINE:\n\n      Patients undergo diffusion-weighted MRI within 4 weeks of radiation start (baseline), during\n      the second week of radiation therapy, during the fourth week of radiation therapy, and at 3\n      months after radiation therapy (post-treatment). Patients also undergo standard of care\n      4-dimensional (4D) computed tomography (CT) and fludeoxyglucose F 18 (FDG)-positron emission\n      tomography (PET) at the same time points."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be able to undergo MRI imaging; contrast application will be determined\n             according to institutional guidelines; patients with locally advanced lung cancer\n             (stage II - IIIB) or locally recurrent lung cancer (following surgery) who are\n             scheduled to receive external beam radiation therapy for at least 6 weeks\n\n          -  Tumor visible on planning CT scan\n\n          -  Negative pregnancy test for women of childbearing potential prior to study entry\n\n        Exclusion Criteria:\n\n          -  Patients requiring continuous supplemental oxygen\n\n          -  Patients with metal implants including pace makers and defibrillators\n\n          -  Patients with cerebral aneurysm clips or middle ear implant\n\n          -  Patients with pain pump, a programmable shunt, or non-surgical metal (i.e. a foreign\n             body)\n\n          -  Claustrophobic patients\n\n          -  Prior radiotherapy to body area under investigation\n\n          -  No vulnerable populations will be enrolled (prisoners, children, pregnant females, or\n             institutionalized individuals)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059889", 
            "org_study_id": "MCC-20000190", 
            "secondary_id": "HM20000190"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)", 
                "description": "Undergo diffusion-weighted MRI", 
                "intervention_name": "diffusion-weighted magnetic resonance imaging", 
                "intervention_type": "Device", 
                "other_name": "diffusion-weighted MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)", 
                "description": "Undergo 4D CT", 
                "intervention_name": "4-dimensional computed tomography", 
                "intervention_type": "Device", 
                "other_name": "4D-CT"
            }, 
            {
                "arm_group_label": "Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)", 
                "description": "Undergo FDG-PET", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": "18FDG, 2-F18-fluoro-2-deoxyglucose, 63503-12-8, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, fluorodeoxyglucose F 18, Fluorodeoxyglucose F18"
            }, 
            {
                "arm_group_label": "Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)", 
                "description": "Undergo FDG-PET", 
                "intervention_name": "FDG-PET", 
                "intervention_type": "Device", 
                "other_name": "FDG-PET, PET, PET scan, tomography, emission computed"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deoxyglucose"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Lung", 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "contact": {
                "email": "lwalker@mcvh-vcu.edu", 
                "last_name": "Linda Walker, BS, CCRP", 
                "phone": "804-628-2204"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University Massey Cancer Center"
            }, 
            "investigator": {
                "last_name": "Elisabeth Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer", 
        "overall_contact": {
            "email": "eweiss@mcvh-vcu.edu", 
            "last_name": "Elisabeth Weiss, MD", 
            "phone": "804-628-1939"
        }, 
        "overall_official": {
            "affiliation": "Massey Cancer Center", 
            "last_name": "Elisabeth Weiss, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A paired sample t-test could be applied to test the difference between MRI, CT, and PET-CT contours. Parameters used for comparison will include volume size, volume overlap, such as Dice similarity coefficients and Jaccard index, and surface distance maps including Hausdorff distance.", 
                "measure": "Measurement of gross tumor volume and involved lymph nodes", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "Patients will be classified into responders and non-responders based on their PET signal which will serve as the reference method for response assessment. Although this is a little different from the three group analysis of variance (ANOVA) used in the power calculation, it is expected that there will be similar high power when the partial responders and non-responders are combined. Receiver operating characteristic (ROC) analysis will be used to define a threshold of apparent diffusion coefficient (ADC) change to stratify between metabolic responders vs. non-responders.", 
                "measure": "Change in functional response", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 3 months"
            }, 
            {
                "description": "A paired sample t-test will be used.", 
                "measure": "Spatial concordance of multimodality imaging for whole image registration", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "A paired sample t-test will be used. ROC analysis will be performed only for radioresistant sub-volumes to identify which diffusion weighted-MRI functional signal thresholds correlate with levels of tumor activity defined on PET.", 
                "measure": "Temporospatial registrations of radioresistant sub-volumes", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Fourth week ADC change will be compared to metabolic response defined by the fourth week PET using three group ANOVA and ROC analysis.", 
            "measure": "Change in ADC", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 4 weeks"
        }, 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}